T&R Biofab

티앤알바이오팹 · 246710

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$71.8M (₩99.1B)

Overview

T&R Biofab makes three-dimensional bioprinting systems and the materials that go with them, including bioink, a gel-like substance that keeps living cells alive during printing, to produce biodegradable scaffolds that help the body regenerate tissue.

Its products serve the regenerative medicine field, and it also supplies surgical products that apply the same biomaterial know-how to a range of surgical procedures. Listed on KOSDAQ, Korea's tech and small-cap board, the company runs three business lines, regenerative medicine, bio-surgical solutions, and cosmetics, with the cosmetics segment added as a nearer-term revenue source while longer-horizon programs such as organoids and cell therapies remain in development.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$19.5M
▲ +453.3% YoY
Operating profit · FY2025
−US$6.6M
Loss narrowed
Net income · FY2025
−US$25.3M
Loss widened

Revenue

  • FY2023US$3.8M
  • FY2024US$3.5M
  • FY2025US$19.5M

Operating profit

  • FY2023−US$9.2M
  • FY2024−US$9.6M
  • FY2025−US$6.6M

Net income

  • FY2023−US$9.7M
  • FY2024−US$5.6M
  • FY2025−US$25.3M

Key ratios (FY2025)

ROE
-151.4%
Debt/Eq
301.7%
Op. margin
-33.6%
Net margin
-129.6%
Rev. YoY
▲ +453.3%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.